Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer
出版年份 2020 全文链接
标题
Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer
作者
关键词
Breast cancer, Interplay, Inhibitor, Therapy
出版物
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 210, Issue -, Pages 112954
出版商
Elsevier BV
发表日期
2020-10-30
DOI
10.1016/j.ejmech.2020.112954
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Synthesis and biological evaluation of 6-phenylpurine linked hydroxamates as novel histone deacetylase inhibitors
- (2020) Dizhong Chen et al. BIOORGANIC CHEMISTRY
- Advances in anti-breast cancer drugs and the application of nano-drug delivery systems in breast cancer therapy
- (2020) Xiaolin Fang et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Discovery of a novel series of imidazo[1′,2’:1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors
- (2020) Chen Shi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Substituted 1-methyl-4-phenylpyrrolidin-2-ones – Fragment-based design of N-methylpyrrolidone-derived bromodomain inhibitors
- (2020) J.P. Hilton-Proctor et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening
- (2020) Jian Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo
- (2020) Chuanlong Guo et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- PD-L1/PD-1 axis as a potent therapeutic target in breast cancer
- (2020) Shima Bastaki et al. LIFE SCIENCES
- Opposing Functions of BRD4 Isoforms in Breast Cancer
- (2020) Shwu-Yuan Wu et al. MOLECULAR CELL
- Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors
- (2020) Qifei Li et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a hydrazone moiety as potent PLK1 inhibitors
- (2020) Zhiwei Li et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer
- (2020) Xin Jing et al. EXPERIMENTAL CELL RESEARCH
- The Design and Synthesis of a Highly Selective and In Vivo Capable Inhibitor of the Second Bromodomain (BD2) of the Bromodomain and Extra Terminal Domain (BET) Family of Proteins
- (2020) Alex Preston et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Optimisation of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor
- (2020) Jonathan Thomas Seal et al. JOURNAL OF MEDICINAL CHEMISTRY
- 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma
- (2019) Anisha Viswanathan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Association Between Reimbursement Incentives and Physician Practice in Oncology
- (2019) Aaron P. Mitchell et al. JAMA Oncology
- Discovery of Novel Bromophenol–Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer
- (2019) Chuanlong Guo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold
- (2019) Ghada F. Elmasry et al. BIOORGANIC CHEMISTRY
- Design, synthesis and activity evaluation of indole-based double – Branched HDAC1 inhibitors
- (2019) Qiuqiong Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo
- (2019) Yudi Xiong et al. BIOMEDICINE & PHARMACOTHERAPY
- Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing
- (2019) Jian Liu et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
- (2019) Ai Ueda et al. LABORATORY INVESTIGATION
- Genomic characterization of metastatic breast cancers
- (2019) François Bertucci et al. NATURE
- Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
- (2019) Wei Xiong Wen et al. PLoS One
- Vaccine Therapies for Breast Cancer
- (2019) Erin E. Burke et al. Surgical Oncology Clinics of North America
- Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors
- (2019) Gibeom Nam et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of [1,2,4]triazolo[1,5-a]pyrimidine derivatives as new bromodomain-containing protein 4 (BRD4) inhibitors
- (2019) Shuai Wang et al. CHINESE CHEMICAL LETTERS
- Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy
- (2019) Zhuang Yang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Drug repurposing for breast cancer therapy: Old weapon for new battle
- (2019) Sadhna Aggarwal et al. SEMINARS IN CANCER BIOLOGY
- Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors
- (2019) Yi Zhong et al. BIOORGANIC CHEMISTRY
- Small molecule HDAC inhibitors: Promising agents for breast cancer treatment
- (2019) Meiling Huang et al. BIOORGANIC CHEMISTRY
- BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response
- (2019) Guillaume P. Andrieu et al. CANCER LETTERS
- Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity
- (2019) Prakruti Trivedi et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity
- (2019) Xin Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor
- (2019) Uttara Soumyanarayanan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold
- (2019) Xiao Lv et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Precision Medicine and Targeted Therapies in Breast Cancer
- (2019) Ian Greenwalt et al. Surgical Oncology Clinics of North America
- Design and synthesis of 4-(2,3-dihydro-1 H -benzo[ d ]pyrrolo[1,2- a ]imidazol-7-yl)- N -(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships
- (2018) Yan Wang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer
- (2018) Xinyu Ren et al. CANCER BIOLOGY & THERAPY
- HPV vaccination and the effects on rates of HPV-related cancers
- (2018) Jessica St. Laurent et al. CURRENT PROBLEMS IN CANCER
- Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors
- (2018) Xuxing Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity
- (2018) Jie Zhou et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival “early on” in neoadjuvant treatment of breast cancer
- (2018) Karen Drukker et al. CANCER IMAGING
- Precision Medicine in Hormone Receptor-Positive Breast Cancer
- (2018) Azadeh Nasrazadani et al. Frontiers in Oncology
- Recent Advances in the Treatment of Breast Cancer
- (2018) Christy W. S. Tong et al. Frontiers in Oncology
- Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1
- (2018) Yanhong Chen et al. BIOORGANIC CHEMISTRY
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- A New Challenge for Radiologists: Radiomics in Breast Cancer
- (2018) Paola Crivelli et al. Biomed Research International
- Design, synthesis and biological evaluation of novel pyrazolochalcones as potential modulators of PI3K/Akt/mTOR pathway and inducers of apoptosis in breast cancer cells
- (2017) Anver Basha Shaik et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 2-substituted 1 H -benzo[ d ]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity
- (2017) Jie Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 1-(3-aryl-4-chlorophenyl)-3-( p -aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings
- (2017) Wenlu Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
- (2017) Angela Chou et al. GUT
- Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
- (2017) Katarzyna Guzik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lysine acetylation and cancer: A proteomics perspective
- (2017) Jeovanis Gil et al. Journal of Proteomics
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design and purification of active truncated phosphoinositide 3-kinase gamma protein constructs for structural studies
- (2017) A. Vujičić Žagar et al. PROTEIN EXPRESSION AND PURIFICATION
- 3-Substituted-4-hydroxycoumarin as a new scaffold with potent CDK inhibition and promising anticancer effect: Synthesis, molecular modeling and QSAR studies
- (2016) Nehad A. Abdel Latif et al. BIOORGANIC CHEMISTRY
- Use of complementary and alternative medicine and breast cancer survival in the Health, Eating, Activity, and Lifestyle Study
- (2016) Marian L. Neuhouser et al. BREAST CANCER RESEARCH AND TREATMENT
- Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination
- (2016) Jason S. L. Yu et al. DEVELOPMENT
- A novel quinazolinone chalcone derivative induces mitochondrial dependent apoptosis and inhibits PI3K/Akt/mTOR signaling pathway in human colon cancer HCT-116 cells
- (2016) Zahoor Ahmad Wani et al. FOOD AND CHEMICAL TOXICOLOGY
- Prognostic significance of PD-L1 and PD-L2 in breast cancer
- (2016) Mauricio Z. Baptista et al. HUMAN PATHOLOGY
- The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
- (2016) Yasushi Taniguchi INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules
- (2016) Jeremy L. Yap et al. JOURNAL OF MEDICINAL CHEMISTRY
- BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
- (2016) Ballachanda N Devaiah et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
- (2016) Ballachanda N Devaiah et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks
- (2016) Corinne Chabalier-Taste et al. Oncotarget
- Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond
- (2016) Cristina Migali et al. Therapeutic Advances in Medical Oncology
- CDK4/6 inhibitors in breast cancer
- (2015) Tim Dukelow et al. ANTI-CANCER DRUGS
- PARP inhibitors for anticancer therapy
- (2014) Nicola Curtin BIOCHEMICAL SOCIETY TRANSACTIONS
- Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts
- (2014) S. C. Tate et al. CLINICAL CANCER RESEARCH
- Molecular Markers for Breast Cancer: Prediction on Tumor Behavior
- (2014) Bruna Karina Banin Hirata et al. DISEASE MARKERS
- Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates
- (2014) Aifeng Lyu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PARP inhibitors in ovarian cancer: Current status and future promise
- (2014) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
- (2014) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
- (2013) Berit Maria Müller et al. BMC CANCER
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
- (2013) J. Rader et al. CLINICAL CANCER RESEARCH
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Breast Cancer
- (2013) Cindy B. Matsen et al. JAMA Surgery
- The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
- (2012) Mike De Vos et al. BIOCHEMICAL PHARMACOLOGY
- Systemic therapy options in BRCA mutation-associated breast cancer
- (2012) Soley Bayraktar et al. BREAST CANCER RESEARCH AND TREATMENT
- Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
- (2012) R Y Tsang et al. BRITISH JOURNAL OF CANCER
- Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer
- (2012) V. Maire et al. CANCER RESEARCH
- Small-Molecule Inhibition of BRDT for Male Contraception
- (2012) Martin M. Matzuk et al. CELL
- Breast cancer management: Past, present and evolving
- (2012) M Akram et al. INDIAN JOURNAL OF CANCER
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
- (2011) J. D. Jensen et al. ANNALS OF ONCOLOGY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- HDAC6 is required for invadopodia activity and invasion by breast tumor cells
- (2010) Mercedes Rey et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- Overexpression of T lymphoma invasion and metastasis 1 predict renal cell carcinoma metastasis and overall patient survival
- (2010) Liang Zhao et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Challenges, controversies, breakthroughs
- (2010) Lisa Hutchinson Nature Reviews Clinical Oncology
- Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
- (2010) Klaus Strebhardt NATURE REVIEWS DRUG DISCOVERY
- Targeting homologous recombination repair defects in cancer
- (2010) Bastiaan Evers et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Adjuvant endocrine therapy for premenopausal women with breast cancer
- (2009) Shannon Puhalla et al. BREAST
- Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer
- (2009) M Loddo et al. BRITISH JOURNAL OF CANCER
- PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
- (2009) K. Kalinsky et al. CLINICAL CANCER RESEARCH
- PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality
- (2009) Elena López-Knowles et al. INTERNATIONAL JOURNAL OF CANCER
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer
- (2008) Thomas D. Penning et al. JOURNAL OF MEDICINAL CHEMISTRY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started